Skip to main navigation .hamburger .st0{fill:none;stroke:#FFFFFF;stroke-width:0.5;} Media & Investors Overview Press Releases Events & Presentations Corporate Governance Documents & Charters Management Board of Directors Committee Composition Annual Meeting Materials Financials & Filings SEC Filings Annual Reports Stock Information Stock Quote & Chart Analyst Coverage Investor FAQs Contact INVESTORS Corporate Presentation View Presentation Stock Quote NASDAQ: EDIT $34.01 Change0 (0.00%) Volume196 52 Week High$99.95 52 Week Low$28.71 Nov 23, 2021 4:00 PM EST Data Provided by Refinitiv. Minimum 15 minutes delayed. Upcoming Events 4th Annual Evercore ISI HealthCONx Conference Dec 2, 2021 at 9:40 AM EST Click here for Webcast Add to Outlook Add to Google Calendar Recent News November 12, 2021 Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting November 8, 2021 Editas Medicine Announces Third Quarter 2021 Results and Business Updates November 4, 2021 Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition >> Press Release See All See all SIGN UP FOR E-MAIL ALERTS SIGN UP For Investors: Ron Moldaver Editas Medicine, Inc. Phone: 617.401.9052 E-mail: ir@editasmed.com For Media: Cristi Barnett Editas Medicine, Inc. Phone: 617.401.0133 E-mail: cristi.barnett@editasmed.com >> Main Navigation Research and Pipeline CRISPR Gene Editing For Patients Who We Are Join Our Team Investors ©Copyright 2021 Editas Medicine >> Footer Menu Get in Touch Investors Privacy Policy Terms of Use